Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPO-RAs and Anti-CD20 Antibody in Pediatric ITP
NCT05718856Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab and Ortuzumab in primary immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2023; status: recruiting.
02
Drugs
rituximabOrtuzumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05718856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718856.